APRI (Aprinoia Therapeutics) EV-to-OCF: 0.00 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics EV-to-OCF?

Aprinoia Therapeutics APRI EV-to-OCF is 0.00 as of Aug. 09, 2026.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aprinoia Therapeutics's Enterprise Value is $0.00 Mil. Aprinoia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.74 Mil. Therefore, Aprinoia Therapeutics's EV-to-OCF for today is 0.00.

The historical rank and industry rank for Aprinoia Therapeutics's EV-to-OCF or its related term are showing as below:

APRI's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.45
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-09), Aprinoia Therapeutics's stock price is $0.00. Aprinoia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Aprinoia Therapeutics's PE Ratio (TTM) for today is N/A.

Aprinoia Therapeutics  (NAS:APRI) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Aprinoia Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Aprinoia Therapeutics's share price for today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Aprinoia Therapeutics EV-to-OCF Related Terms

Aprinoia Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EV-to-OCF Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-OCF
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-OCF 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics EV-to-OCF Calculation

Aprinoia Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.000/-14.739
=0.00

Aprinoia Therapeutics's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of 0.00 mean?
Aprinoia Therapeutics (APRI) has a EV-to-OCF of 0.00 as of Aug. 09, 2026.
Is Aprinoia Therapeutics' EV-to-OCF too high?
Aprinoia Therapeutics' current EV-to-OCF is 0.00.
How does Aprinoia Therapeutics' EV-to-OCF compare to ?
Aprinoia Therapeutics' EV-to-OCF of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Aprinoia Therapeutics's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current EV-to-OCF is 0.00 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.